14.85
-1.07%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ChengDu Sheng Nuo Biotec Co
Its shares trade on Shanghai under the ticker 688117.SS. It has been listed since 3 June 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥741.3m and net income of CN¥165.8m. At that date it held total assets of CN¥1.93bn and shareholders' equity of CN¥1.06bn.
Cheng Du Sheng Nuo Biotec Co., Ltd. engages in research, development, production, customized manufacturing, and sale of polypeptide generic drug raw materials and preparation products. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-06-03. The firm's products target areas including immunology, digestive tract, antivirus, gynecology, diabetes, cardio-cerebrovascular, rare diseases, orthopedics and other fields. The firm is also engaged in customized peptide production services for customers, customized production services for peptide APIs and preparations, and technology transfer services for peptide drug production. The firm also provides small-molecule chemical drug Levosimendan preparations on behalf of processing, Levosimendan bulk drug production and export sales business.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Jun 2021
- Employees
- 879
- Website
- snbiopharm.com ↗
Leadership
Pay as last reported
- Mr. Yongjun WenChairman of the Board, General Manager, since 2013CN¥881,500
- Mr. Li WuFinance Director, Deputy General Manager, Director, since 2022CN¥332,900
- Mr. Xiaohai YuDeputy General Manager, Secretary of the Board, Director, since 2022CN¥557,100
- Ms. Xiaoli WangDeputy General Manager, Director, since 2013CN¥716,500
- Mr. Changliang LuDeputy General ManagerCN¥640,500
- Mr. Zhonggang MaDeputy General ManagerCN¥714,100
- Mr. Yafei SongDirector
- Mr. Fasheng WenDirector, since 2016CN¥675,300
- Ms. Xia LiuIndependent Director
- Mr. Yingkai TangIndependent Director
- Mr. Zhengsong XuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ChengDu Sheng Nuo Biotec employs 879 full-time employees in Chengdu, Sichuan.
- The company focuses on polypeptide generic drug raw materials and preparation products.
- ChengDu Sheng Nuo Biotec offers customized peptide production services for customers.
Weaknesses
- ChengDu Sheng Nuo Biotec's business is limited to polypeptide generic drugs and preparation products.
- The company's products target specific medical fields like immunology and diabetes.
- ChengDu Sheng Nuo Biotec has no mention of international expansion plans.
Opportunities
- ChengDu Sheng Nuo Biotec can expand into rare disease drug development.
- The firm's customized peptide production services can attract more clients.
- ChengDu Sheng Nuo Biotec can leverage its Levosimendan preparations for export sales.
Threats
- ChengDu Sheng Nuo Biotec faces competition in the polypeptide drug market.
- The company's reliance on specific medical fields may limit growth.
- ChengDu Sheng Nuo Biotec must comply with pharmaceutical regulations in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.